The drug will target specific genetic mutations prevalent in certain types of cancers
Zydus has launched Olaparib, a PARP inhibitor, under the brand name IBYRA in India. The drug will target specific genetic mutations prevalent in certain types of cancers, paving the way for a more tailored and effective treatment approach.
Zydus has collaborated with MedGenome for comprehensive HRD testing. This along with a year-long treatment of IBYRA has been capped at Rs 3 lakhs as compared to the cost of around Rs 72 lakhs by the innovator.
Dr Sharvil Patel, MD, Zydus Lifesciences, said, “For patients newly diagnosed with these specific cancers, the right diagnosis and the right treatment early on can give them a big advantage in the fight against cancers. Our patient support focus in launching IBYRA helps them with both cutting-edge diagnosis for HRD-positive cancer and precision therapy in the most affordable way. We believe this will reduce the disease burden for the patients in a significant way.”
